Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Moderna, Inc.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
Johnson & Johnson has added a manufacturing base in India’s Biological E as part of a global supply chain for its COVID-19 vaccine candidate. While Biological E will make 400-500 million dosages for the US firm, it has licensed for development another SARS-CoV-2 vaccine candidate from US-based Baylor College of Medicine.
Administration suggests Operation Warp Speed vaccines come with US FDA review speed advantage, but the agency backtracks on that assertion. FDA may need to get creative to ensure it has enough staff to quickly review all vaccines, expert says.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.